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Background: The single and combined effects of scavenger receptor-BI (SR-BI), ATP-binding cassette transporter
(ABC) A1 and G1 on cholesterol efflux from Chinese Hamster Ovary (CHO) cells were investigated.
Results: When apolipoproteinA-I (apoA-I) was used as an acceptor, ABCA1 overexpression led to an increase in
total cholesterol (TC) in medium which is attributable to a 2-fold increase in free cholesterol (FC) content. When
high-density lipoprotein 3 (HDL3) was used as an acceptor, SR-BI overexpression not only promoted FC efflux, but
also promoted the uptake of cholesteryl ester (CE) into cells, resulting in no TC varieties in medium. Overexpression
of ABCG1 increased both the FC and CE levels in medium. However, when apoA-I and HDL3 were both used as
acceptors, coexpression of SR-BI has no effect on ABCA1-mediated increased FC and TC accumulation in medium.
Interestingly, coexpression of SR-BI with ABCG1 blocked the ABCG1-mediated cholesterol efflux to HDL3, mostly by
promoting the reuptake of CE from the medium. Furthermore, co-immunoprecipitation experiments revealed that
SR-BI interacted with ABCG1 in BHK cells overexpressing ABCG1 and SR-BI.
Conclusions: We found SR-BI associates with ABCG1 and inhibits ABCG1-mediated cholesterol efflux from cells to
HDL3.Background
Reverse cholesterol transport (RCT) is assumed to play a
critical role in the pathogenesis of atherosclerosis [1]. Cel-
lular cholesterol efflux, by which cholesterol is transported
from peripheral cells to high-density lipoprotein (HDL)
acceptor molecules, is the first step of RCT [2]. ATP-
binding cassette transporter (ABC) A1, G1 and scavenger
receptor-BI (SR-BI) are three important mediators of chol-
esterol efflux. ABCA1 exports cholesterol and phospho-
lipid to lipid-poor apolipoproteins and initiates HDL
formation by lipidating apolipoproteinA-I (apoA-I) [3].
However, ABCA1 interacts poorly with HDL2 and HDL3
particles, which constitute the bulk of the plasma HDL.
Another two cell surface transporters, ABCG1 and SR-BI,
have been described to export cholesterol to
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reproduction in any medium, provided the orstimulates the bidirectional flux of cholesterol between
cells and lipoproteins [4], while ABCG1 has been shown
to promote free cholesterol (FC) efflux from macrophage
to HDL and increase the accumulation of cholesteryl ester
(CE) in medium as a result of lecithin-cholesterol acyl-
transferase (LCAT)-mediated cholesterol esterification [5].
It has been reported that mice lacking ABCA1 expres-
sion in macrophages developed accelerated atherosclerosis
[6]. Conversely, mice with macrophage overexpression of
ABCA1 have decreased atherosclerosis [7]. Mice lacking
ABCG1 have evidence of lipid accumulation in certain tis-
sue macrophages [8,9]. Furthermore, transplantation of
bone marrow from SR-BI deficient (SR-BI −/−) mice into
LDL receptor −/− or apoE −/− mice have shown an in-
crease in atherosclerosis [10-12]. Taken together, these
findings suggest that all three transporters involving
macrophage ABCA1, ABCG1 and SR-BI may exert pro-
tective functions in atherosclerosis. In addition, many
reports have indicated a synergistic relationship between
ABCA1 and ABCG1 in peripheral tissues, where ABCA1
lipidates any lipid-poor/free apoA-I to generate nascent ortd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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strates for ABCG1-mediated cholesterol export [13-15].
However, the relationships between SR-BI and the two
ABC transporters are not well understood. The current
study was undertaken to compare the roles of SR-BI and
the two ABC transporters in promoting mass cholesterol
efflux and determine a possible interaction between the
SR-BI- and ABC transporter-mediated cholesterol efflux
pathways in vitro. We found coexpression of SR-BI with
ABCG1 blocked the ABCG1-mediated cholesterol efflux
to HDL3, mostly by promoting the reuptake of CE
from the medium. Furthermore, co-immunoprecipitation
experiments revealed that SR-BI interacted with ABCG1
in BHK cells overexpressing ABCG1 and SR-BI, which
might play roles in maintaining cellular cholesterol
homeostasis.
Results
The single effects of SR-BI, ABCA1 and ABCG1 on cellular
cholesterol efflux
It has been reported that lipid-free apoA-I is the lipid
acceptor of ABCA1-mediated cholesterol efflux [16-18],
while SR-BI [19] and ABCG1 [8,20] were identified as
being mediators of cholesterol efflux to mature HDL,
but not to lipid-free apoA-I in vitro. Therefore, we used
apoA-I as lipid acceptors in ABCA1 transfected cells
and HDL3 as lipid acceptors in SR-BI or ABCG1 trans-
fected cells. As shown in Figure 1, SR-BI overexpression
not only increased the accumulation of FC (Figure 1A),
but also decreased the accumulation of CE in medium
(Figure 1B), resulting in no total cholesterol (TC) var-
ieties in medium (Figure 1C). These data gave us a clue
that SR-BI overexpression might not only promote FC
efflux, but also promote the uptake of CE into cells. In
addition, ABCA1 overexpression led to an increase in
TC in medium (Figure 1C), in large part attributable to
a 2-fold increase in FC content (Figure 1A), while over-
expression of ABCG1 increased both the FC (Figure 1A)
and CE (Figure 1B) levels in medium.
The effects of SR-BI on ABCA1-mediated cellular
cholesterol efflux
Because ABCA1 and ABCG1 act in a cooperative fash-
ion to promote cellular cholesterol efflux [13], we next
determined whether SR-BI might facilitate ABCA1-
mediated cellular cholesterol efflux. Thus, we coex-
pressed SR-BI and ABCA1 in CHO cells and determined
the cholesterol efflux to apoAI and HDL3 (apoA-I and
HDL3 were both used as acceptors). As shown in
Figure 2, coexpression of SR-BI with ABCA1 has no ef-
fect on ABCA1-mediated increased FC (Figure 2A) and
TC (Figure 2B) accumulation in medium. Also, the CE
levels in medium were not changed in SR-BI and ABCA1
cotransfected cells compared with cells overexpressingABCA1 alone (Figure 2C). These data indicated that
SR-BI overexpression has no effect on ABCA1-mediated
cellular cholesterol efflux to apoAI and HDL3 in vitro.
Moreover, the expression levels of ABCA1 were similar
in cells transfected with ABCA1 alone or ABCA1 plus
SR-BI (Figure 2D), which indicates that our findings were
not attributable to a difference in ABCA1 expression
levels.
The effects of SR-BI on ABCG1-mediated cellular
cholesterol efflux
To evaluate the role of SR-BI on ABCG1-mediated chol-
esterol efflux, we coexpressed SR-BI and ABCG1 in
CHO cells and determined the cholesterol efflux to
HDL3. As shown in Figure 3, coexpression of SR-BI with
ABCG1 blocked the ABCG1-mediated cholesterol efflux
to HDL3, and it seems that this effect of SR-BI was
mostly achieved by promoting the reuptake of CE from
the medium. This was similar to previous findings, in
which it was indicated SR-BI inhibits ABCG1-stimulated
CE accumulation in medium in an LCAT-dependent
manner by using HEK293 cell model [21].
SR-BI co-immunoprecipitated with ABCG1 in BHK cells
overexpressing SR-BI and ABCG1
Co-immunoprecipitation experiments with cell lysates
from SR-BI and ABCG1 co-transfected BHK cells were
performed to confirm whether SR-BI and ABCG1 were
present in the same complex. The immunoprecipitates
were then analyzed by western blot with antibodies
against SR-BI. As shown in Figure 4, SR-BI were
detected in the anti-ABCG1 immunoprecipitates from
the cell lysates of transfected BHK cells. These results
suggested that SR-BI associates with ABCG1 in BHK
cells overexpressing SR-BI and ABCG1.
Discussion
The purpose of the present study was to compare the
roles of SR-BI, ABCA1 and ABCG1 singly or together in
mediating cholesterol efflux from cells in vitro. We
found that SR-BI associates with ABCG1 and inhibits
ABCG1-mediated cholesterol efflux from cells to HDL3,
and that overexpression of SR-BI has no effect on
ABCA1-mediated cellular cholesterol efflux to apoAI
and HDL3 in vitro.
It has been reported that ABCA1 exports cholesterol
and phospholipid to lipid-poor apolipoproteins, and
interacts poorly with HDL2 and HDL3 particles [3].
ABCG1 and SR-BI have been described to export choles-
terol to phospholipid-containing acceptors, including
HDL [4]. In our study, overexpression of ABCA1 pro-
moted the efflux of FC from cells to apoA-I and over-
expression of ABCG1 not only promoted the FC efflux
to HDL3, but also increased the CE levels in medium. A
Figure 1 The single effects of SR-BI, ABCA1 and ABCG1 on cellular cholesterol efflux. CHO cells were transiently transfected with plasmid
constructs expressing SR-BI, ABCA1, ABCG1 or empty vector. 24 h after transfection, the cells were incubated with 150 μg/ml HDL3 (HDL3 chase) or
10 μg/ml apoA-I (apoA-I chase) for 24 h in Opti-MEM I Medium. Cholesterol efflux was determined by measuring the increased free cholesterol (FC, A),
cholesteryl ester (CE, B), and total cholesterol (TC, C) in medium. Values are means ± SD of three independent experiments. *p < 0.05, **p < 0.01.
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mulation of CE in medium as a result of LCAT-
mediated cholesterol esterification [5], so it is possible
that the increase in CE induced by ABCG1 in our study
might be attributable to the active LCAT, which is
retained in the HDL3 particles. Previous findings have
shown that ABCA1 and ABCG1 synergize to mediate
cellular cholesterol export to lipoproteins [13], so we ini-
tially hypothesized that SR-BI and ABCA1 might also
act synergistically on cholesterol efflux, because the nas-
cent HDL particles formed from the ABCA1-mediated
cholesterol efflux to apoA-I might serve as an acceptor
for SR-BI-mediated cholesterol efflux. To assess the hy-
pothesis, we performed cotransfection with SR-BI and
ABCA1 cDNAs in CHO cells and then treated the cells
with cholesterol acceptor apoA-I and HDL3. Out of our
expectation, we found ABCA1 promoted the efflux of
FC from cells, but SR-BI has no effect on ABCA1-stimulated increased FC accumulation in medium. Fur-
thermore, we co-transfected SR-BI and ABCG1 cDNAs
into CHO cells and found an interesting phenomenon
that SR-BI inhibited ABCG1-mediated CE accumulation
in medium. This was similar to a previous finding, in
which it was shown SR-BI promotes cellular reuptake of
the CE that initially undergoes ABCG1-mediated choles-
terol efflux to HDL3 containing active LCAT [21]. In
this context, we thought it is possible that SR-BI and
ABCG1 might talk to each other in cells. Therefore, we
performed co-immunoprecipitation experiments with
cell lysates from SR-BI and ABCG1 co-transfected BHK
cells to confirm whether SR-BI and ABCG1 were present
in the same complex. In our expectation, we found SR-
BI associates with ABCG1 in transfected BHK cells.
Based on our findings, it is possible that in our experi-
mental conditions, SR-BI interacted with ABCG1 and
therefore inhibited ABCG1-mediated cholesterol efflux.
SR-BI
ABCA1





Figure 2 SR-BI does not affect ABCA1-mediated cellular cholesterol efflux. CHO cells were transiently transfected with SR-BI alone, ABCA1
alone, and SR-BI plus ABCA1 (co-transfection). 24 h after transfection, cholesterol efflux was initiated by the addition of HDL3 (150 μg protein/ml)
and apoA-I (10 μg/ml) to medium for 24 h. The increased FC (A), CE (B) and TC (C) mass in medium were determined. Values are means ± SD of
three independent experiments. * p < 0.05, ** p < 0.01. D shows the western blots of SR-BI and ABCA1 protein in vector transfected, SR-BI
transfected, ABCA1 transfected and cotransfected cells.
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SR-BI and ABCG1 can have physiological relevance in
tissues expressing ABC transporters, such as macro-
phages or liver [16,22]. But future studies need to be
performed to confirm the effect of SR-BI on ABCA1- or
ABCG1-mediated cholesterol efflux to apoA-I or HDL
in macrophages and hepatocytes under basal physio-
logical conditions because the expression levels of SR-BI
and ABC transporters were different among different
cell types. In addition, we performed experiments in
nonploarized cells, it is possible that in polarized cells,
such as hepatocytes, SR-BI and ABC transporters may
be expressed on different sides of the cell and the futile
cycle created by the joint overexpression of SR-BI and
ABCG1 in CHO cells and BHK cells might be avoided.
Besides, we also found SR-BI promoted FC efflux to
HDL3, but this was counteracted by an increased uptake
of CE into cells and thus no significant change in TC in
medium. This was similar to previous findings that
SR-BI promoted a bidirectional flux of isotopic choles-
terol between cells and lipoproteins [23,24], but our
study extends earlier findings suggesting that SR-BI sin-
gly does not play important roles in promoting net chol-
esterol efflux to HDL3. Although SR-BI did not promote
net cholesterol efflux, it is possible that the cholesterolchanges mediated by SR-BI may have effects on cellular
cholesterol homeostasis, because CE entering the cells
would not play regulatory roles corresponding to that
resulting from the efflux of FC.
Conclusions
Our data suggested SR-BI associates with ABCG1 and
appear to inhibit ABCG1-mediated CE accumulation in
medium, but does not affect ABCA1-stimulated choles-
terol efflux from cells to apoA-I or HDL3 in vitro, which
might play roles in maintaining cellular cholesterol
homeostasis. Further studies on the interactions between
endogenous SR-BI and ABC transporters in promoting
cholesterol efflux in vivo need to be conducted.
Methods
Isolation of HDL from plasma
HDL3 fractions were isolated from normolipidemic
human plasma by sequential ultracentrifugation at a
density of 1.210 g/ml and dialyzed against PBS contain-
ing 1 mM EDTA [25]. The integrity of the isolated
HDL3 was checked by 0.8% agarose gel electrophoresis.
Cell culture and transfection
Chinese hamster ovary (CHO) cells purchased from
ATCC were cultured in F-12 medium (Hyclone)
SR-BI
ABCG1





Figure 3 SR-BI inhibits ABCG1-mediated cellular cholesterol efflux. CHO cells were transiently transfected with SR-BI alone, ABCG1 alone,
and SR-BI plus ABCG1 (co-transfection). 24 h after transfection, cholesterol efflux was initiated by the addition of HDL3 (150 μg protein/ml) to
medium for 24 h. The increased FC (A), CE (B) and TC (C) mass in medium were determined. Values are means ± SD of three independent
experiments. * p < 0.05, ** p < 0.01. D shows the western blots of SR-BI and ABCG1 protein in vector transfected, SR-BI transfected, ABCG1
transfected and cotransfected cells.
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Gibco) and 2 mM L-glutamine. Cells grown to 80-90%
confluence were transiently transfected with similar
amounts of control empty vector (pcDNA3.1+), murine
SR-BI, ABCA1 or ABCG1 cDNA alone combined with
empty vector (1:1), or both SR-BI and ABCA1 cDNA
(1:1), or both SR-BI and ABCG1 cDNA (1:1) using Lipo-
fectamine 2000 (Invitrogen) according to the manufac-
turer`s instructions. BHK-G (BHK cells stably expressing
mifepristone inducible ABCG1) cells were kindly
provided by Dr. Xian-cheng Jiang, SUNY Downstate
Medical Center, USA. 10 nM mifepristone in 1% fattySR-BI (82 kDa)
Figure 4 Co-immunoprecipitation of SR-BI with ABCG1 in BHK
cells overexpressing SR-BI and ABCG1. The cell lysates from the
transfected BHK cells were immunoprecipitated with anti-ABCG1
antibody. The immunoprecipitates were then analyzed by western
blot with antibody against SR-BI.acid-free bovine serum albumin was used for 18–20 hr
to induce ABCG1 expression. Then BHK-G cells were
transiently transfected with SR-BI using Lipofectamine
2000 and incubated for 24–36 hr prior to performing
the further experiments. For all experiments, cells
cultured for 4–10 passages were used.Western blot analysis
Transfected cells were washed with phosphate-buffered
saline (PBS) and lysed in lysis buffer containing 50 mM
Tris, pH 7.5, 1.0 mM EDTA, 150 mM NaCl, 0.1% SDS, 1%
TritonX-100, 1% Sodium deoxycholate, and 1 × proteinase
inhibitor cocktail (Invitrogen). After heating at 95°C for
5 min, cell-lysate samples of equal protein concentration
were subjected to SDS-PAGE and transferred onto polyvi-
nylidene fluoride (PVDF) membranes (Millipore, USA) by
electroblotting. ABCA1, ABCG1 and SR-BI proteins were
detected using anti-ABCA1 polyclonal antibody (1:200 di-
lution, Santa Cruz Biotechnology), anti-ABCG1 polyclonal
antibody (1:300, Santa Cruz Biotechnology), or anti-SR-BI
monoclonal antibody (1:2000, Novus Biological Inc.). Pri-
mary antibodies were detected using a peroxidase-
conjugated anti-mouse, anti-goat or anti-rabbit antibody
and revealed by ECL Substrate (Pierce).
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Cholesterol efflux assays were carried out as described
with modifications [5]. In brief, 24 hours after transfection,
the cells were incubated for 24 h in Opti-MEM serum-free
medium (Invitrogen) in the presence or absence of HDL3
(150 μg protein/ml) and/or apoA-I (10 μg/ml, Sigma).
After the incubation, the mass of cholesterol in medium
was determined by using Cholesterol/Cholesteryl Ester
Quantitation Kit (Biovision) according to the manufac-
turer`s instructions. Cells were lysed and the protein con-
tent was determined by the BCA method.
Co-immunoprecipitation and Western blot
BHK cells transfected with ABCG1 and SR-BI were used
for immunoprecipitation experiments. Immunoprecipi-
tation of SR-BI and ABCG1 protein was performed by
using the Protein G Immunoprecipitation Kit (Roche)
according to the manufacturer’s instructions. The immu-
noprecipitated proteins were then subjected to western
blotting to analyze the target antigens in complex mix-
tures of proteins.
Statistical analysis
Statistical analysis was performed by one-way analysis of
variance (ANOVA) test with the GraphPad Prism
programme ver.4.0. Results are expressed as means ± SD.
P values less than 0.05 were considered significant.
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